-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the drug in the digestive system has been successfully reported
.
Jianmin Group issued an announcement that the company's Class 1.
1 innovative Chinese medicine drug Tongxian Granules was approved for clinical trials
.
According to the latest data from Minai.
com, the sales of over-the-counter drugs in the terminal digestive system of China's urban physical pharmacies exceeded 15 billion yuan in 2021, and it is expected to reach a new high
in 2022.
From the perspective of manufacturer pattern, Taiji Group, Chongqing Fuling Pharmaceutical, Jiangzhong Pharmaceutical, Zhangzhou Pian Zixi Pharmaceutical, Jiangxi Kang'enbei Traditional Chinese Medicine, and Ma Yinglong Pharmaceutical Group ranked in the top five
.
11 of the TOP20 are exclusive products, 1 billion products are expected to add two more fierce generals, 17 brands have sales of more than 100 million yuan
.
Since 2018, only 3 proprietary drugs in the digestive system have been approved for marketing, in addition, 2 products are under review, and new drugs such as Yangzijiang Pharmaceutical Group's Jiangsu Longfengtang Traditional Chinese Medicine Cleansing and Wenzhong Tablets, Tasly Pharmaceutical Group| Jiangsu Institute of Traditional Chinese Medicine Guankang Granules are in phase II clinical stage
.
.
Jianmin Group issued an announcement that the company's Class 1.
1 innovative Chinese medicine drug Tongxian Granules was approved for clinical trials
.
According to the latest data from Minai.
com, the sales of over-the-counter drugs in the terminal digestive system of China's urban physical pharmacies exceeded 15 billion yuan in 2021, and it is expected to reach a new high
in 2022.
From the perspective of manufacturer pattern, Taiji Group, Chongqing Fuling Pharmaceutical, Jiangzhong Pharmaceutical, Zhangzhou Pian Zixi Pharmaceutical, Jiangxi Kang'enbei Traditional Chinese Medicine, and Ma Yinglong Pharmaceutical Group ranked in the top five
.
11 of the TOP20 are exclusive products, 1 billion products are expected to add two more fierce generals, 17 brands have sales of more than 100 million yuan
.
Since 2018, only 3 proprietary drugs in the digestive system have been approved for marketing, in addition, 2 products are under review, and new drugs such as Yangzijiang Pharmaceutical Group's Jiangsu Longfengtang Traditional Chinese Medicine Cleansing and Wenzhong Tablets, Tasly Pharmaceutical Group| Jiangsu Institute of Traditional Chinese Medicine Guankang Granules are in phase II clinical stage
.
The 15 billion digestive system patent drug market reached a new high, with Tai Chi and Jiangzhong leading the way
Sales of proprietary drugs in the digestive system of physical pharmacies in China in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
According to the latest data from Minai.
com, in recent years, the market of proprietary drugs in the terminal digestive system of China's urban physical pharmacies has maintained stable growth, with sales exceeding 15 billion yuan in 2021 and is expected to reach a new high in 2022, a year-on-year increase of 2.
76%.
com, in recent years, the market of proprietary drugs in the terminal digestive system of China's urban physical pharmacies has maintained stable growth, with sales exceeding 15 billion yuan in 2021 and is expected to reach a new high in 2022, a year-on-year increase of 2.
76%.
From the perspective of manufacturer pattern, Taiji Group, Chongqing Fuling Pharmaceutical, Jiangzhong Pharmaceutical, Zhangzhou Pian Zixi Pharmaceutical, Jiangxi Kang'enbei Traditional Chinese Medicine, and Ma Yinglong Pharmaceutical Group ranked in the top five
.
Among them, Taiji Group, Chongqing Fuling Pharmaceutical and Zhangzhou Pian Zixi Pharmaceutical both grew by more than 10%.
.
Among them, Taiji Group, Chongqing Fuling Pharmaceutical and Zhangzhou Pian Zixi Pharmaceutical both grew by more than 10%.
In recent years, the market share of the top 5 subcategories of over-the-counter drugs in the digestive system of China's urban physical pharmacies
Source: Competition pattern of drug terminals in China's urban physical pharmacies
Among the 13 subcategories of proprietary drugs in the digestive system, the five subcategories of anti-heat drugs, gastric drugs (gastritis, ulcers), stomach digestion, liver disease drugs and hemorrhoids drugs are the best-sellers, with a total market share of nearly 80%.
It is worth noting that the market share of anti-heat agents has steadily increased in recent years, surpassing gastric drugs (gastritis, ulcers) in 2021 and becoming the first subcategory of proprietary drugs in the digestive system, and the market share is expected to further expand
in 2022.
It is worth noting that the market share of anti-heat agents has steadily increased in recent years, surpassing gastric drugs (gastritis, ulcers) in 2021 and becoming the first subcategory of proprietary drugs in the digestive system, and the market share is expected to further expand
in 2022.
1 billion varieties add two more fierce generals! 11 exclusive products "preemptive" the TOP20
2022E Top 20 proprietary drug products in the digestive system of China's urban physical pharmacies (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
The sales of TOP20 products have exceeded 100 million yuan, Huo Xiang Zhengqi oral liquid and stomach tablets have exceeded 1 billion yuan, and Tablet Zixi and Enteritis Ning Tablets are expected to become 1 billion products
with stable growth.
From the perspective of growth rate, Huo Xiang Zhengqi Oral Liquid, Pian Zixi, Ginseng Jian Spleen and Stomach Granules, Pian Zixi Capsules, and Anti-inflammatory Choleretic Tablets all exceeded 10%.
with stable growth.
From the perspective of growth rate, Huo Xiang Zhengqi Oral Liquid, Pian Zixi, Ginseng Jian Spleen and Stomach Granules, Pian Zixi Capsules, and Anti-inflammatory Choleretic Tablets all exceeded 10%.
From the perspective of treatment subcategories, there are five best-selling subcategories such as heat repellents, gastric drugs (gastritis, ulcers), and stomach digestion, each with 3 on the list, 2 for constipation, 1 each for diabetes, intestinal and biliary drugs
.
.
It is worth mentioning that there are 11 exclusive varieties in the TOP20 products, such as Pian Zixi, Enteritis Ning Tablets, Ma Yinglong Musk Hemorrhoid Cream, Sanjiu Gastric Tai Granules, Huo Xiang Zhengqi Drop Pills, etc.
, involving 10 enterprises
such as Zhangzhou Pian Zixi Pharmaceutical, Jiangxi Kang'en Bei Traditional Chinese Medicine, Ma Yinglong Pharmaceutical Group, and Tasly Pharmaceutical Group.
, involving 10 enterprises
such as Zhangzhou Pian Zixi Pharmaceutical, Jiangxi Kang'en Bei Traditional Chinese Medicine, Ma Yinglong Pharmaceutical Group, and Tasly Pharmaceutical Group.
2022E Top 20 Proprietary Drug Brands in the Digestive System of Chinese Urban Physical Pharmacies (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
Note: Less than 100 million yuan is indicated by *
The sales of 17 brands exceeded 100 million yuan, and Taiji Group's Chongqing Fuling Pharmaceutical's Huoxiang Zhengqi Oral Liquid, Jiangzhong Pharmaceutical's Stomach Digestion Tablets, and Zhangzhou Pian Zixi Pharmaceutical's Pian Zixi ranked in the top three
.
.
Sales of Chinese urban physical pharmacies in recent years (100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
Pian Zixi is an exclusive product of Zhangzhou Pian Zi Xi Pharmaceutical, and the terminal sales scale of physical pharmacies in Chinese cities have grown steadily in recent years, and are expected to exceed the 1 billion mark
in 2022.
The company said that at present, it has formed a pattern of multi-format aggregation in the health field, and will continue to deeply implement the strategy of "multi-core driven, two-way development", continue to consolidate and deepen the core position of Pian Zixi, create a new growth pole of Pian Zi Xi brand Angong Niuhuang Pill, promote the further upgrading of the cosmetics industry of Pian Zi Xi, focus on creating a core series of explosive products, consolidate the foundation internally to tap the potential to create a new growth pole, seek external industrial expansion, and promote the company's high-quality development
.
in 2022.
The company said that at present, it has formed a pattern of multi-format aggregation in the health field, and will continue to deeply implement the strategy of "multi-core driven, two-way development", continue to consolidate and deepen the core position of Pian Zixi, create a new growth pole of Pian Zi Xi brand Angong Niuhuang Pill, promote the further upgrading of the cosmetics industry of Pian Zi Xi, focus on creating a core series of explosive products, consolidate the foundation internally to tap the potential to create a new growth pole, seek external industrial expansion, and promote the company's high-quality development
.
Sales of Enteritis Tablets in China's urban physical pharmacies in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in China's urban physical pharmacies
Enteritis Ning tablets are used for diarrhea caused by humid heat in the large intestine, and are the exclusive products
of Jiangxi Kang'en Bei traditional Chinese medicine.
According to data from Minai.
com, the terminal sales of enteritis tablets in China's urban physical pharmacies have exceeded 900 million yuan in 2021, and it is expected to reach a new high in 2022 and enter the ranks of 1 billion
echelons.
For a long time, Kangbei has continued to promote scientific and technological innovation, including the secondary development of large varieties, and the secondary development and evidence-based medical research of key proprietary Chinese medicine products such as Musk Macaroni Drop Pills, Hanfang Hexomethyl Tablets, Compound Houttuynia Mixture and Enteritis Ning Tablets, accumulating momentum for the
company's development.
of Jiangxi Kang'en Bei traditional Chinese medicine.
According to data from Minai.
com, the terminal sales of enteritis tablets in China's urban physical pharmacies have exceeded 900 million yuan in 2021, and it is expected to reach a new high in 2022 and enter the ranks of 1 billion
echelons.
For a long time, Kangbei has continued to promote scientific and technological innovation, including the secondary development of large varieties, and the secondary development and evidence-based medical research of key proprietary Chinese medicine products such as Musk Macaroni Drop Pills, Hanfang Hexomethyl Tablets, Compound Houttuynia Mixture and Enteritis Ning Tablets, accumulating momentum for the
company's development.
New drugs broke out, Yangtze River, Tasly, Jianmin.
.
.
The heat strikes
.
.
The heat strikes
Since 2018, he has mainly developed proprietary drugs in the digestive system
Source: Minai.
com China Drug Clinical Trial Publicity Database, CDE official website
com China Drug Clinical Trial Publicity Database, CDE official website
A few days ago, the drug in the digestive system was successfully reported
.
Jianmin Group issued an announcement that the company's class 1.
1 traditional Chinese medicine innovative drug Tongxi granules were approved for clinical trials, the product prescription originated from the hospital preparation of medical institutions, the main function is liver thinning and clearing fever, and gastric hypothermia, used for liver and stomach depression
.
Up to now, the company has invested 6.
081 million yuan in R&D
.
.
Jianmin Group issued an announcement that the company's class 1.
1 traditional Chinese medicine innovative drug Tongxi granules were approved for clinical trials, the product prescription originated from the hospital preparation of medical institutions, the main function is liver thinning and clearing fever, and gastric hypothermia, used for liver and stomach depression
.
Up to now, the company has invested 6.
081 million yuan in R&D
.
Since 2018, only 3 products of proprietary drugs in the digestive system have been approved for marketing, all of which are reported as new drugs, among which, Qili Gastroshu capsules of Jianmin Pharmaceutical Group are gastric drugs (gastritis, ulcer), Shandong Phoenix Pharmaceutical's Qi Huang capsules and Beijing Wuhe Boao Pharmaceutical's mulberry total alkaloid tablets are diabetes drugs
.
.
In addition, Jiangxi Qingfeng Pharmaceutical's Olanti Gastrokang tablets and Xinjiang Uygur Pharmaceutical's Xingqi Tanical capsules are under review
.
A number of new drugs, such as Yangtze River Pharmaceutical Group's Jiangsu Longfengtang Traditional Chinese Medicine Colon Cleansing and Wenzhong Tablets, Zhejiang Jingxin Pharmaceutical's Rehabilitation New Enteric-coated Capsules, Tasly Pharmaceutical Group| Jiangsu Institute of Traditional Chinese Medicine, and many other new drugs are in the phase II clinical stage
.
.
A number of new drugs, such as Yangtze River Pharmaceutical Group's Jiangsu Longfengtang Traditional Chinese Medicine Colon Cleansing and Wenzhong Tablets, Zhejiang Jingxin Pharmaceutical's Rehabilitation New Enteric-coated Capsules, Tasly Pharmaceutical Group| Jiangsu Institute of Traditional Chinese Medicine, and many other new drugs are in the phase II clinical stage
.
Source: CDE official website, Minainet database, etc
Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; All sales are based on the average retail price of the product
.
If there is any omission, welcome to correct!
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; All sales are based on the average retail price of the product
.
If there is any omission, welcome to correct!
